hVIVO reports Phase IIb data of universal flu vaccine

hVIVO plc (LSE:HVO) said a single dose of FLU-v met the primary endpoint of reducing the incidence of mild to moderate influenza disease vs. placebo in the Phase IIb FLU-v 004 trial (p=0.035). The company expects to begin Phase III testing of the universal flu vaccine in 2020.

NIH's National Institute of Allergy and Infectious Diseases (NIAID), which collaborated with hVIVO and Seek Group (London, U.K.) to conduct FLU-v 004, will publish detailed data in a peer-reviewed journal...